These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1083 related items for PubMed ID: 28647167

  • 1. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4753-4760. PubMed ID: 28647167
    [Abstract] [Full Text] [Related]

  • 2. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB, den Hartog G, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    PLoS One; 2018 Aug 24; 13(4):e0191261. PubMed ID: 29672552
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.
    BMC Infect Dis; 2015 Oct 06; 15():409. PubMed ID: 26437712
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
    Quiambao BP, Bavdekar A, Dubey AP, Jain H, Kolhe D, Bianco V, Miller JM, Van der Wielen M.
    Hum Vaccin Immunother; 2017 Mar 04; 13(3):636-644. PubMed ID: 28152332
    [Abstract] [Full Text] [Related]

  • 13. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB, Marinovic AB, van der Klis FR, van Rooijen DM, van Maurik M, Stoof SP, Sanders EA, Berbers GA.
    Vaccine; 2016 Dec 07; 34(50):6309-6315. PubMed ID: 27817957
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
    Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL.
    BMC Infect Dis; 2020 Jun 18; 20(1):426. PubMed ID: 32552685
    [Abstract] [Full Text] [Related]

  • 16. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.
    Knuf M, Helm K, Kolhe D, Van Der Wielen M, Baine Y.
    Vaccine; 2018 May 31; 36(23):3286-3295. PubMed ID: 29724511
    [Abstract] [Full Text] [Related]

  • 17. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    BMC Med Res Methodol; 2019 Jan 05; 19(1):1. PubMed ID: 30611213
    [Abstract] [Full Text] [Related]

  • 18. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C.
    Vaccine; 2020 May 08; 38(22):3902-3908. PubMed ID: 32284274
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP, Block SL, Essink B, Barbi S, Smolenov I, Keshavan P.
    Vaccine; 2019 Jul 26; 37(32):4460-4467. PubMed ID: 31279564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.